High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1189-1195

  Zheng, Huirong ^a   Zhang, Li ^a   Li, Lingjiang ^a,c   Liu, Peng ^b   Gao, Junling ^d   Liu, Xiaoyun ^b   Zou, Juan ^a   Zhang, Yan ^a   Liu, Jun ^a   Zhang, Zhijun ^e   Li, Zexuan ^a   Men, Weiwei ^f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Hunan Cancer Hospital   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^f XINJIANG NORMAL UNIVERSITY   (China)

Author keywords

Depression; Magnetic resonance spectroscopy; Myo inositol; RTMS

Indexed keywords

ESCITALOPRAM; INOSITOL;

ADULT; ARTICLE; BRAIN METABOLISM; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; ONSET AGE; PREFRONTAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; REMISSION; THERAPY RESISTANCE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

EID: 77956450416     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.06.009     Document Type: Article

References (54)

1. Ali A.B., Rossier J., Staiger J.F., Audinat E. Kainate receptors regulate unitary ipscs elicited in pyramidal cells by fast-spiking interneurons in the neocortex. J Neurosci 2001, 21:2992-2999.
2. Alvarez J.C., Gluck N., Arnulf I., Quintin P., Leboyer M., Pecquery R., et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther 1999, 66:617-624.
3. Auld D.S., Robitaille R. Glial cells and neurotransmission: an inclusive view of synaptic function. Neuron 2003, 40:389-400.
4. Barker A.T., Jalinous R., Freeston I.L. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985, 1:1106-1107.
5. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440.
6. Beck A.T., Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974, 7:151-169.
7. Belmaker R.H., Livne A., Agam G., Moscovich D.G., Grisaru N., Schreiber G., et al. Role of inositol-1-phosphatase inhibition in the mechanism of action of lithium. Pharmacol Toxicol 1990, 66(Suppl 3):76-83.
8. Bench C.J., Frackowiak R.S., Dolan R.J. Changes in regional cerebral blood flow on recovery from depression. Psychol Med 1995, 25:247-261.
9. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007, 52:46-54.
10. Botteron K.N., Raichle M.E., Drevets W.C., Heath A.C., Todd R.D. Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry 2002, 51:342-344.
11. Cecil K.M., DelBello M.P., Sellars M.C., Strakowski S.M. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. J Child Adolesc Psychopharmacol 2003, 13:545-555.
12. Coupland N.J., Ogilvie C.J., Hegadoren K.M., Seres P., Hanstock C.C., Allen P.S. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005, 57:1526-1534.
13. Davanzo P., Yue K., Thomas M.A., Belin T., Mintz J., Venkatraman T.N., et al. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry 2003, 160:1442-1452.
14. Davis S., Thomas A., Perry R., Oakley A., Kalaria R.N., O'Brien J.T. Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. J Neurol Neurosurg Psychiatry 2002, 73:556-560.
15. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000, 126:413-431.
16. Drevets W.C., Bogers W., Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using pet measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002, 12:527-544.
17. Duman R.S. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998, 44:324-335.
18. Einat H., Karbovski H., Korik J., Tsalah D., Belmaker R.H. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology 1999, 144:158-162. (Berl).
19. Fitzgerald P.B., Brown T.L., Marston N.A., Daskalakis Z.J., De Castella A., Kulkarni J. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003, 60:1002-1008.
20. Frey R., Metzler D., Fischer P., Heiden A., Scharfetter J., Moser E., et al. Myo-inositol in depressive and healthy subjects determined by frontal 1h-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 1998, 32:411-420.
21. George M.S., Nahas Z., Molloy M., Speer A.M., Oliver N.C., Li X.B., et al. A controlled trial of daily left prefrontal cortex tms for treating depression. Biol Psychiatry 2000, 48:962-970.
22. Grill-Spector K., Henson R., Martin A. Repetition and the brain: neural models of stimulus-specific effects. Trends Cogn Sci 2006, 10:14-23.
23. Gross M., Nakamura L., Pascual-Leone A., Fregni F. Has repetitive transcranial magnetic stimulation (rtms) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rtms studies. Acta Psychiatr Scand 2007, 116:165-173.
24. Gruber S., Frey R., Mlynarik V., Stadlbauer A., Heiden A., Kasper S., et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1h-mrs at 3 tesla. Invest Radiol 2003, 38:403-408.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
26. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., et al. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (gdnf) synthesis and release in rat c6 glioblastoma cells. J Neurochem 2001, 79:25-34.
27. Kennedy S.H., Evans K.R., Kruger S., Mayberg H.S., Meyer J.H., McCann S., et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001, 158:899-905.
28. Kim H., McGrath B.M., Silverstone P.H. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (pi-cycle) to psychiatric disorders-focus on magnetic resonance spectroscopy (mrs) studies. Hum Psychopharmacol 2005, 20:309-326.
29. Knable M.B., Barci B.M., Bartko J.J., Webster M.J., Torrey E.F. Molecular abnormalities in the major psychiatric illnesses: classification and regression tree (crt) analysis of post-mortem prefrontal markers. Mol Psychiatry 2002, 7:392-404.
30. Kornstein S.G., Schneider R.K. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001, 62(Suppl 16):18-25.
31. Kumar A., Thomas A., Lavretsky H., Yue K., Huda A., Curran J., et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry 2002, 159:630-636.
32. Lam R.W., Chan P., Wilkins-Ho M., Yatham L.N. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry 2008, 53:621-631.
33. Levine J., Barak Y., Gonzalves M., Szor H., Elizur A., Kofman O., et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995, 152:792-794.
34. Lisanby S.H., Gutman D., Luber B., Schroeder C., Sackeim H.A. Sham tms: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry 2001, 49:460-463.
35. Luborzewski A., Schubert F., Seifert F., Danker-Hopfe H., Brakemeier E.L., Schlattmann P., et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res 2007, 41:606-615.
36. Renshaw P.F. Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 2002, 51:195-207.
37. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000, 48:830-843.
38. Michael N., Gosling M., Reutemann M., Kersting A., Heindel W., Arolt V., et al. Metabolic changes after repetitive transcranial magnetic stimulation (rtms) of the left prefrontal cortex: a sham-controlled proton magnetic resonance spectroscopy (1h mrs) study of healthy brain. Eur J Neurosci 2003, 17:2462-2468.
39. Miguel-Hidalgo J.J., Baucom C., Dilley G., Overholser J.C., Meltzer H.Y., Stockmeier C.A., et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000, 48:861-873.
40. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998, 95:13290-13295.
41. Padberg F., Zwanzger P., Keck M.E., Kathmann N., Mikhaiel P., Ella R., et al. Repetitive transcranial magnetic stimulation (rtms) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology 2002, 27:638-645.
42. Pandey G.N., Ren X., Pandey S.C., Dwivedi Y., Sharma R., Janicak P.G. Hyperactive phosphoinositide signaling pathway in platelets of depressed patients: effect of desipramine treatment. Psychiatry Res 2001, 105:23-32.
43. Pascual-Leone A., Rubio B., Pallardo F., Catala M.D. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996, 348:233-237.
44. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000, 48:766-777.
45. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
46. Sander J.B., McCarty C.A. Youth depression in the family context: familial risk factors and models of treatment. Clin Child Fam Psychol Rev 2005, 8:203-219.
47. Schummers J., Yu H., Sur M. Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. Science 2008, 320:1638-1643.
48. Schutter D.J. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009, 39:65-75.
49. Shah P.J., Ebmeier K.P., Glabus M.F., Goodwin G.M. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 1998, 172:527-532.
50. Shimon H., Agam G., Belmaker R.H., Hyde T.M., Kleinman J.E. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997, 154:1148-1150.
51. Silvanto J., Pascual-Leone A. State-dependency of transcranial magnetic stimulation. Brain Topogr 2008, 21:1-10.
52. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007, 68:1062-1070.
53. Thomas A.J., O'Brien J.T., Davis S., Ballard C., Barber R., Kalaria R.N., et al. Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 2002, 59:785-792.
54. Yukimasa T., Yoshimura R., Tamagawa A., Uozumi T., Shinkai K., Ueda N., et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 2006, 39:52-59.